The two companies entered a courtroom duel, each side wielding scientific evidence and legal arguments. Therasense claimed their design was a significant improvement, making blood testing faster and more accurate. BD countered that similar technology already existed, and Therasense was simply trying to monopolize the market.

But there was another twist in the tale. During the legal battle, evidence emerged that Therasense might have withheld some crucial information from the patent office. This potential "inequitable conduct" could invalidate their patents, even if the technology itself was innovative.

The case went back and forth, with a rollercoaster of decisions from different courts. At first, some courts sided with Therasense, upholding the validity of their patents. However, later appeals courts questioned Therasense's conduct and started chipping away at their patent protections.

Finally, in 2014, the dust settled. The courts ultimately ruled that Therasense's patents were unenforceable due to the potential inequitable conduct. BD was free to develop and sell their own blood test strips without infringing on Therasense's patents.

The Therasense v. Becton Dickinson case serves as a valuable lesson. While protecting inventions through patents is important, the process requires complete transparency. Withholding information from patent offices can backfire, even if the underlying technology is innovative.

Learn More - Top Interesting Patent Lawsuits